Horizon Kinetics’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Horizon Kinetics’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,178	Closed	-$31K	–	513
2017 Q2	$31K	Hold	3,178	–	–	﹤0.01%	504
2017 Q1	$77K	Hold	3,178	–	–	﹤0.01%	492
2016 Q4	$102K	Hold	3,178	–	–	﹤0.01%	493
2016 Q3	$159K	Hold	3,178	–	–	﹤0.01%	486
2016 Q2	$135K	Hold	3,178	–	–	﹤0.01%	504
2016 Q1	$209K	Hold	3,178	–	–	0.01%	482
2015 Q4	$198K	Hold	3,178	–	–	﹤0.01%	474
2015 Q3	$213K	Buy	3,178 +763	+32%	+$62.3K	﹤0.01%	457
2015 Q2	$235K	Hold	2,415	–	–	﹤0.01%	465
2015 Q1	$226K	Buy	2,415 +890	+58%	+$75.7K	﹤0.01%	478
2014 Q4	$136K	Hold	1,525	–	–	﹤0.01%	502
2014 Q3	$105K	Hold	1,525	–	–	﹤0.01%	507
2014 Q2	$87K	Hold	1,525	–	–	﹤0.01%	523
2014 Q1	$60K	Buy	+1,525	New	+$65.3K	﹤0.01%	530

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Horizon Kinetics's MACK Position: Q3 2017 in Review

Horizon Kinetics sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,178 shares — an estimated $31K sold.

Horizon Kinetics first reported a position in MACK in Q1 2014 and held it in 14 quarters. The position peaked at $235K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Horizon Kinetics reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Horizon Kinetics sold 3,178 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $31K.
Horizon Kinetics first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2014 and held it in 14 quarters.
Horizon Kinetics's Merrimack Pharmaceuticals, Inc. position peaked at $235K in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Horizon Kinetics's 13F filing for Q3 2017, filed 14 Nov 2017.